The Board proposes to open the rule for development to comprehensively review the rule for any necessary or needed changes of a technical or substantive nature or changes necessary to make the rule clearer, and for the specific purpose to review the ...

 

DEPARTMENT OF HEALTH

Board of Pharmacy

RULE NO.:RULE TITLE:

64B16-27.700Definition of Compounding

PURPOSE AND EFFECT: The Board proposes to open the rule for development to comprehensively review the rule for any necessary or needed changes of a technical or substantive nature or changes necessary to make the rule clearer, and for the specific purpose to review the impact, if any, to the rule due to the recently enacted federal Compounding Quality Act, which is Title I of the Drug Quality and Security Act. Pub. L. No. 113-54, 127 Stat. 587 [H.R. 3204] (Nov. 27 2013). And, to also determine if there are any necessary changes needed to subsection (3) in relation to the quantity of compounded drugs that may be compounded for purposes of Office Use Compounding.

SUBJECT AREA TO BE ADDRESSED: Definition of Compounding.

RULEMAKING AUTHORITY: 465.005, 465.0155, 465.022 FS.

LAW IMPLEMENTED: 465.003(13); 465.0155, 465.022 FS.

IF REQUESTED IN WRITING AND NOT DEEMED UNNECESSARY BY THE AGENCY HEAD, A RULE DEVELOPMENT WORKSHOP WILL BE NOTICED IN THE NEXT AVAILABLE FLORIDA ADMINISTRATIVE REGISTER.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE DEVELOPMENT AND A COPY OF THE PRELIMINARY DRAFT, IF AVAILABLE, IS: Tammy Collins, Acting Executive Director, Board of Pharmacy, 4052 Bald Cypress Way, Bin C04, Tallahassee, Florida 32399-3254

THE PRELIMINARY TEXT OF THE PROPOSED RULE DEVELOPMENT IS NOT AVAILABLE.